We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
IQVIA Holdings (IQV) Stock Up 55.4% Over a Year: Here's Why
Read MoreHide Full Article
IQVIA Holdings Inc.’s (IQV - Free Report) shares have charted a solid trajectory, appreciating 55.4% over the past year, surpassing 8.8% growth of the industry it belongs to and 33.1% rally of the Zacks S&P 500 composite.
Image Source: Zacks Investment Research
Let’s delve into the factors that have contributed to the company’s outperformance.
Consecutive Earnings & Revenue Beat
IQVIA Holdings came up with better-than-expected earnings and revenue performance in all the four quarters of 2020 as well as first-quarter 2021. The company’s bottom line continued to benefit from improvement in operational efficiency and decline in interest expenses. Strength across the Technology & Analytics Solutions segment boosted the top line.
Upbeat 2021 Guidance
IQVIA Holdings raised its 2021 guidance. Revenues are now expected within $13.2-$13.5 billion compared with the prior guided range of $12.55-$12.90 billion. The current Zacks Consensus Estimate of $13.31 billion lies within the updated guidance.
Adjusted earnings per share are now expected between $8.50 and $8.75 compared with the prior guided range of $7.89-$8.20. The current Zacks Consensus Estimate of $8.69 lies within the updated guidance.
Adjusted EBITDA is now anticipated between $2.900 billion and $2.965 billion compared with the prior guided range of $2.760-$2.840 billion.
Robust Set of Capabilities
IQVIA Holdings has a strong healthcare-specific global IT infrastructure, analytics-driven clinical development capabilities, a robust real-world solutions ecosystem, and a growing set of proprietary clinical as well as commercial applications that allow it to grow and retain relationships with healthcare stakeholders. The company’s combined offerings of research and development, and commercial services have been helping it develop trusted relationships, in turn resulting in a diversified base of more than 10,000 clients in over 100 countries.
Long-term (three to five years) expected earnings per share growth rate for Equifax, Charles River and TransUnion is projected at 14%, 15.5%, and 20.9%, respectively.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.
Image: Shutterstock
IQVIA Holdings (IQV) Stock Up 55.4% Over a Year: Here's Why
IQVIA Holdings Inc.’s (IQV - Free Report) shares have charted a solid trajectory, appreciating 55.4% over the past year, surpassing 8.8% growth of the industry it belongs to and 33.1% rally of the Zacks S&P 500 composite.
Image Source: Zacks Investment Research
Let’s delve into the factors that have contributed to the company’s outperformance.
Consecutive Earnings & Revenue Beat
IQVIA Holdings came up with better-than-expected earnings and revenue performance in all the four quarters of 2020 as well as first-quarter 2021. The company’s bottom line continued to benefit from improvement in operational efficiency and decline in interest expenses. Strength across the Technology & Analytics Solutions segment boosted the top line.
Upbeat 2021 Guidance
IQVIA Holdings raised its 2021 guidance. Revenues are now expected within $13.2-$13.5 billion compared with the prior guided range of $12.55-$12.90 billion. The current Zacks Consensus Estimate of $13.31 billion lies within the updated guidance.
Adjusted earnings per share are now expected between $8.50 and $8.75 compared with the prior guided range of $7.89-$8.20. The current Zacks Consensus Estimate of $8.69 lies within the updated guidance.
Adjusted EBITDA is now anticipated between $2.900 billion and $2.965 billion compared with the prior guided range of $2.760-$2.840 billion.
Robust Set of Capabilities
IQVIA Holdings has a strong healthcare-specific global IT infrastructure, analytics-driven clinical development capabilities, a robust real-world solutions ecosystem, and a growing set of proprietary clinical as well as commercial applications that allow it to grow and retain relationships with healthcare stakeholders. The company’s combined offerings of research and development, and commercial services have been helping it develop trusted relationships, in turn resulting in a diversified base of more than 10,000 clients in over 100 countries.
Zacks Rank and Other Stocks to Consider
IQVIA Holdings currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Other top-ranked stocks in the broader Zacks Business Services sector include Equifax (EFX - Free Report) , Charles River (CRAI - Free Report) and TransUnion (TRU - Free Report) , each carrying a Zacks Rank #2.
Long-term (three to five years) expected earnings per share growth rate for Equifax, Charles River and TransUnion is projected at 14%, 15.5%, and 20.9%, respectively.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.
Click here for the 4 trades >>